172 related articles for article (PubMed ID: 36948945)
1. Appropriate antibiotic therapy is a predictor of outcome in patients with Stenotrophomonas maltophilia blood stream infection in the intensive care unit.
Lai JJ; Siu LK; Chang FY; Lin JC; Yu CM; Wu RX; Wang CH
J Microbiol Immunol Infect; 2023 Jun; 56(3):624-633. PubMed ID: 36948945
[TBL] [Abstract][Full Text] [Related]
2. Can levofloxacin be a useful alternative to trimethoprim-sulfamethoxazole for treating Stenotrophomonas maltophilia bacteremia?
Cho SY; Kang CI; Kim J; Ha YE; Chung DR; Lee NY; Peck KR; Song JH
Antimicrob Agents Chemother; 2014; 58(1):581-3. PubMed ID: 24126583
[TBL] [Abstract][Full Text] [Related]
3. Clinical outcomes of Stenotrophomonas maltophilia infection treated with trimethoprim/sulfamethoxazole, minocycline, or fluoroquinolone monotherapy.
Junco SJ; Bowman MC; Turner RB
Int J Antimicrob Agents; 2021 Aug; 58(2):106367. PubMed ID: 34058337
[TBL] [Abstract][Full Text] [Related]
4. Stenotrophomonas maltophilia bacteremia and pneumonia at a tertiary-care oncology center: a review of 16 years.
Velázquez-Acosta C; Zarco-Márquez S; Jiménez-Andrade MC; Volkow-Fernández P; Cornejo-Juárez P
Support Care Cancer; 2018 Jun; 26(6):1953-1960. PubMed ID: 29307014
[TBL] [Abstract][Full Text] [Related]
5. Emergence of concurrent levofloxacin- and trimethoprim/sulfamethoxazole-resistant Stenotrophomonas maltophilia: Risk factors and antimicrobial sensitivity pattern analysis from a single medical center in Taiwan.
Wu RX; Yu CM; Hsu ST; Wang CH
J Microbiol Immunol Infect; 2022 Feb; 55(1):107-113. PubMed ID: 33500210
[TBL] [Abstract][Full Text] [Related]
6. Molecular epidemiology and risk factors of Stenotrophomonas maltophilia infections in a Chinese teaching hospital.
Duan Z; Qin J; Liu Y; Li C; Ying C
BMC Microbiol; 2020 Sep; 20(1):294. PubMed ID: 32993493
[TBL] [Abstract][Full Text] [Related]
7. Comparisons between patients with trimethoprim-sulfamethoxazole-susceptible and trimethoprim-sulfamethoxazole-resistant Stenotrophomonas maltophilia monomicrobial bacteremia: A 10-year retrospective study.
Wang CH; Lin JC; Lin HA; Chang FY; Wang NC; Chiu SK; Lin TY; Yang YS; Kan LP; Yang CH; Chan MC; Yeh KM
J Microbiol Immunol Infect; 2016 Jun; 49(3):378-86. PubMed ID: 25081988
[TBL] [Abstract][Full Text] [Related]
8. Emerging importance of multidrug-resistant Stenotrophomonas maltophilia infections in neonatal intensive care unit in a tertiary center in Turkey.
Demirbuğa A; Akgün Karapınar DB; Yaşa B; Çoban A; Öngen B; Dede E; Mete Atasever N; Somer A; Hançerli Törün S
Pediatr Neonatol; 2024 Mar; 65(2):183-187. PubMed ID: 37919104
[TBL] [Abstract][Full Text] [Related]
9. Levofloxacin-resistant Stenotrophomonas maltophilia: risk factors and antibiotic susceptibility patterns in hospitalized patients.
Wang CH; Yu CM; Hsu ST; Wu RX
J Hosp Infect; 2020 Jan; 104(1):46-52. PubMed ID: 31505224
[TBL] [Abstract][Full Text] [Related]
10. Clinical and Microbiologic Outcomes in Patients with Monomicrobial Stenotrophomonas maltophilia Infections.
Nys C; Cherabuddi K; Venugopalan V; Klinker KP
Antimicrob Agents Chemother; 2019 Nov; 63(11):. PubMed ID: 31427300
[No Abstract] [Full Text] [Related]
11. Sulfamethoxazole/trimethoprim versus fluoroquinolones for the treatment of Stenotrophomonas maltophilia bloodstream infections.
Watson L; Esterly J; Jensen AO; Postelnick M; Aguirre A; McLaughlin M
J Glob Antimicrob Resist; 2018 Mar; 12():104-106. PubMed ID: 28964955
[TBL] [Abstract][Full Text] [Related]
12. StenoSCORE: Predicting Stenotrophomonas maltophilia Bloodstream Infections in the Hematologic Malignancy Population.
Karaba SM; Goodman KE; Amoah J; Cosgrove SE; Tamma PD
Antimicrob Agents Chemother; 2021 Jul; 65(8):e0079321. PubMed ID: 34060899
[TBL] [Abstract][Full Text] [Related]
13. Fluoroquinolones versus trimethoprim-sulfamethoxazole for the treatment of Stenotrophomonas maltophilia infections: a systematic review and meta-analysis.
Ko JH; Kang CI; Cornejo-Juárez P; Yeh KM; Wang CH; Cho SY; Gözel MG; Kim SH; Hsueh PR; Sekiya N; Matsumura Y; Lee DG; Cho SY; Shiratori S; Kim YJ; Chung DR; Peck KR
Clin Microbiol Infect; 2019 May; 25(5):546-554. PubMed ID: 30448331
[TBL] [Abstract][Full Text] [Related]
14. Stenotrophomonas maltophilia bacteremia in children: risk factors and mortality rate.
Alsuhaibani M; Aljarbou A; Althawadi S; Alsweed A; Al-Hajjar S
Antimicrob Resist Infect Control; 2021 Jan; 10(1):19. PubMed ID: 33482916
[TBL] [Abstract][Full Text] [Related]
15. Characteristics of Stenotrophomonas maltophilia infection in children in Sichuan, China, from 2010 to 2017.
Wang L; Zhou W; Cao Y; Yang C; Liu H; Chen T; Chen L
Medicine (Baltimore); 2020 Feb; 99(8):e19250. PubMed ID: 32080131
[TBL] [Abstract][Full Text] [Related]
16. Treatment, clinical outcomes, and predictors of mortality among a national cohort of hospitalized patients with Stenotrophomonas maltophilia infection.
Appaneal HJ; Lopes VV; LaPlante KL; Caffrey AR
Public Health; 2023 Jan; 214():73-80. PubMed ID: 36521275
[TBL] [Abstract][Full Text] [Related]
17. Trimethoprim-Sulfamethoxazole Versus Levofloxacin for
Sarzynski SH; Warner S; Sun J; Matsouaka R; Dekker JP; Babiker A; Li W; Lai YL; Danner RL; Fowler VG; Kadri SS
Open Forum Infect Dis; 2022 Feb; 9(2):ofab644. PubMed ID: 35097154
[TBL] [Abstract][Full Text] [Related]
18. Bloodstream infection caused by Stenotrophomonas maltophilia in children.
Kagen J; Zaoutis TE; McGowan KL; Luan X; Shah SS
Pediatr Infect Dis J; 2007 Jun; 26(6):508-12. PubMed ID: 17529868
[TBL] [Abstract][Full Text] [Related]
19. Stenotrophomonas maltophilia: An Emerging Pathogen of the Respiratory Tract.
Kanderi T; Shrimanker I; Mansoora Q; Shah K; Yumen A; Komanduri S
Am J Case Rep; 2020 May; 21():e921466. PubMed ID: 32448864
[TBL] [Abstract][Full Text] [Related]
20. Trimethoprim/Sulfamethoxazole vs Minocycline for the Treatment of Nonurinary Monomicrobial
Hevia EC; Wooten L; Carr AL
Ann Pharmacother; 2024 Jul; 58(7):698-704. PubMed ID: 37776160
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
